Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep;78(14):1443-1457.
doi: 10.1007/s40265-018-0970-y.

Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma

Ronan Flippot  1 , Bernard Escudier  1 , Laurence Albiges  2
Affiliations
Review

Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma

Ronan Flippot et al. Drugs. 2018 Sep.

Abstract

Immune modulatory treatment regimens, led by immune checkpoint inhibitors, have transformed the treatment of clear-cell renal cell carcinoma. First-in-class, the PD-1 inhibitor nivolumab improved overall survival in advanced renal cell carcinoma following prior anti-angiogenic therapy, an important shift in the management of clear-cell renal cell carcinoma. Further improvements of long-term outcomes will be driven by combinations in the first-line setting, including PD-1/PD-L1 associated with antiangiogenic therapies, or PD1/PD-L1 inhibitors with other immune checkpoint inhibitors such as anti-CTLA-4, anti-LAG-3 or TIM-3 targeted therapies. The first two randomized Phase 3 trials assessing these combinations have now challenged sunitinib in first-line setting. First, the CheckMate 214 trial demonstrated an objective response rate and overall survival benefit for the combination of nivolumab plus ipilimumab in the intermediate- and poor-risk patients. Second, the IMMotion 151 study demonstrated a progression-free survival benefit for the atezolizumab plus bevacizumab combination by investigator assessment. Further Phase 3 trials are awaited with tyrosine kinase and immune checkpoint inhibitor combinations. Clinical trials of immune checkpoint inhibitors are also actively investigated in the localized adjuvant or neoadjuvant setting. Nevertheless, the search for biomarkers along with new clinical trial designs will be crucial to better select the patients that may derive the greatest benefit from these advances. The continuing improvement of antitumor immunity comprehension and the emergence of new immune modulatory treatments will deeply change the management of renal cell carcinoma for the years to come.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
    1. Clin Cancer Res. 2017 Sep 15;23(18):5349-5357 - PubMed
    1. Clin Cancer Res. 2016 Nov 15;22(22):5461-5471 - PubMed
    1. Clin Pharmacol Ther. 2017 Aug;102(2):305-312 - PubMed
    1. Melanoma Res. 2015 Aug;25(4):321-7 - PubMed

MeSH terms

LinkOut - more resources